Andaris agent enters renal study

Article

Ultrasound contrast developer Andaris is exploring radiological applications for its Quantison agent. The Nottingham, U.K.-based company has begun a phase II clinical trial to examine the efficiency of the intravenous agent during renal imaging. To be

Ultrasound contrast developer Andaris is exploring radiological applications for its Quantison agent. The Nottingham, U.K.-based company has begun a phase II clinical trial to examine the efficiency of the intravenous agent during renal imaging. To be conducted at the University Hospital Dijkzigt in Rotterdam, the Netherlands, the trial will employ Quantison during renal imaging in patients with hypertension resulting from renal artery stenosis that was proven angiographically.

Quantison, which consists of a 3-micron air-filled albumin microcapsule, was initially designed for myocardial perfusion and cardiac chamber analysis; previous clinical studies have showed good results in both left ventricular opacification and myocardial perfusion, according to the company. In February, company executives said that Quantison might also be suitable for peripheral vascular and general radiology applications (SCAN 2/5/97).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.